P. Bingham

发表

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.

S. Kaiser, M. Kraus, A. Stewart, 2017, Journal of medicinal chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Analysing the output from primary screening.

Andreas Sewing, Philip Gribbon, A. Sewing, 2006, Combinatorial chemistry & high throughput screening.

A fluorescence polarization assay for screening inhibitors against the ribonuclease H activity of HIV-1 reverse transcriptase.

K. Maegley, P. Bingham, G. Nakayama, 2006, Analytical biochemistry.

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

K. Gajiwala, P. Kung, A. Brooun, 2016, Nature Communications.

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquin

K. Gajiwala, N. Sach, P. Kung, 2017, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3 , 4-Dihydroisoquinoline-1 ( 2 H ) ‐ ones as a Novel Class of Enhancer of Zeste Homolog 2 ( EZH 2 ) Inhibitors

P. Kung, S. Yamazaki, M. Edwards, 2016 .

SAH derived potent and selective EZH2 inhibitors.

K. Gajiwala, P. Kung, K. Maegley, 2015, Bioorganic & medicinal chemistry letters.

Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.

W. K. Sonnenburg, P. Kung, Sergei L Timofeevski, 2020, ACS medicinal chemistry letters.

All PARP inhibitors are not equal: An in vitro mechanistic comparison of PF-01367338 to iniparib.

K. Maegley, P. Bingham, H. Thomas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of Medicinal Chemistry.

Comparison of a High-Throughput Mass Spectrometry Method and Radioactive Filter Binding to Assay the Protein Methyltransferase PRMT5.

A. Brooun, K. Maegley, P. Bingham, 2015, Assay and drug development technologies.

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.

Chin Wee Tan, Dharmesh D. Bhuva, Eric C Greenwald, 2023, Cell chemical biology.

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.

W. K. Sonnenburg, P. Kung, M. Gehring, 2020, ACS medicinal chemistry letters.